Apixaban

Bristol Myers Squibb on Thursday released its sales forecast for the current year, with the expected range of between $46 billion and $47.5 billion surpassing analyst expectations of $44.2 billion. The guidance, although representing a decline versus 2025, when revenue reached $48.2 billion, includes continued growth for Eliquis. Sales of the factor Xa inhibitor had been expected to significantly decline this year after BMS and partner Pfizer announced that they will start selling the drug directly to US patients at more than 40% off the current list price following discussions with the Trump administration. Eliquis is also one of the first 10 medicines subject to Medicare price negotiations in the US under the ⁠Inflation Reduction Act, which came into effect on January 1.However, BMS said that sales of Eliquis are predicted to increase between 10% and 15% this year. The company indicated that the product's lower price will help it avoid penalties imposed by the Medicare programme."The broader pricing dynamics starting this year for Eliquis really ‍was the impetus to re-evaluate our pricing strategy," said Chief Commercialisation Officer Adam Lenkowsky. He explained that the price reduction "eliminates the inflationary penalties…of statutory rebates that had been accumulating over many years for the brand and, taken together, the continued increase in Eliquis market share in the [US], coupled with these net pricing changes, they're going to enable Eliquis to be an important driver of growth this year."According to BMS, the outlook for 2026 includes a 12% to 16% revenue decline for its older portfolio of drugs — Abraxane, Revlimid and Sprycel, which are facing generic competition — partially offset by growth from newer products, as well as the uptick for Eliquis. Earnings per share for the current year are seen in the range of $6.05 to $6.35, versus predictions of $6.02 per share.'Data-rich' yearCEO Christopher Boerner called 2026 "data-rich" for the company, adding "our core business is strong and growing, and we have the potential to achieve industry-leading, sustainable growth into the 2030s and beyond."In the final quarter of 2025, sales of BMS's newer drugs rose 16% to $7.4 billion, driven by immuno-oncology products, Camzyos, Breyanzi and Reblozyl. Revenue from older drugs slipped 15% to $5.1 billion, as overall sales increased 1% to $12.5 billion, topping analyst estimates of $12.3 billion.Fourth-quarter sales of Reblozyl climbed 22% to $666 million, Breyanzi lifted 49% to $392 million and revenue from Camzyos surged 59% to $353 million. Meanwhile, the PD-L1 inhibitor Opdivo posted sales of $2.7 billion, up 9% year-on-year, and topping forecasts of $2.3 billion."We made significant progress in 2025, with real momentum in our growth portfolio," said Boerner. However, BMS's biggest seller continues to be one of its older drugs in Eliquis, with revenue in the three-month period growing 8% to $3.5 billion, boosted by higher demand. Net income in the fourth quarter was $1.1 billion, versus just $72 million in the same period of 2024. Meanwhile, net income for the full year was $7.1 billion, compared with a loss of $8.9 billion a year earlier.

Late-Breaking Science Presentation | Poster at #ISC26 The information contained herein represents a summary of the abstract presented at the International Stroke Conference (Poster ISC26). DANBURY, Conn. , Feb. 4, 2026 /PRNewswire/ -- Perosphere Technologies Inc. (Perosphere), a medical technology company developing next-generation coagulation diagnostics, today announced a Late-Breaking Science Poster Presentation at the International Stroke Conference (#ISC26), held February 4–6, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Dr. med. Kamran Hajiyev, an interventional neuroradiologist at Stuttgart Hospital's Neuroradiology Clinic in Germany, presented groundbreaking data which may for the first time, provide evidence of a potential prothrombotic state in patients with acute ischemic stroke (AIS) not seen in stroke-free controls. They also suggest that there may be a variable rate of anticoagulant response among patients treated with direct oral anticoagulants (DOACs) - a potential "poor or non-responder" population. Dr. Hajiyev's team used ClotChek, Perosphere's newly available point-of-care whole blood coagulometer to measure clotting times in this study. ClotChek Clotting Time (CKCT) was assessed in the following patients: AIS +/- DOAC therapy prior to the event, without AIS but on prophylactic DOAC therapy, and normal controls (no AIS, no DOAC). Results showed that both anticoagulated and non-anticoagulated AIS patients showed significantly shorter clotting times (i.e., more coagulation activity) than non-AIS controls (Figure 1). Among patients receiving DOACs, the anticoagulant response differed markedly between those with AIS and those without AIS. Despite ongoing DOAC therapy, patients with AIS exhibited only minimal anticoagulant activity compared with non-AIS patients on DOACs, suggesting a potentially inadequate anticoagulation effect during stroke. "This research provides critical insights on the potential to transform stroke care. For the first time, it offers evidence of a prothrombotic state in stroke patients that may not be detected by standard testing, with significant implications for protecting these very vulnerable patients," said Professor Hans Henkes, Medical Director of the Neuroradiology Clinic at Klinikum Stuttgart. "With the ClotChek information available in the angio suite we start to understand much better the (sometimes missing) efficacy of DOACs and the patient-specific coagulation features." In stroke-free patients on DOACs, CKCT values closely tracked trough and peak drug levels on a population means basis as measured by calibrated anti-factor Xa (anti-Xa), for rivaroxaban (R² = 0.99) and apixaban (R² = 0.98). By contrast, AIS patients on DOACs showed a dissociation between the assays: despite therapeutic anti-Xa levels, CKCT values were below normal, demonstrating lack of meaningful correlation (R² < 0.1). These results suggest that standard anti-Xa assays may overstate the true anticoagulant effect in DOAC patients with breakthrough strokes. Together, the findings highlight a potential poor or non-responder DOAC population with preserved prothrombotic potential and underscores important clinical implications for acute AIS management. "These highly novel findings have significant implications for design of new studies to improve care and outcomes in patients with acute ischemic stroke, particularly in understanding why some patients suffer strokes despite anticoagulation therapy," said Dileep R. Yavagal, MD, Director of Interventional Neurology and Co-Director of Neuroendovascular Surgery at the University of Miami and Jackson Memorial Hospitals and Clinical Professor of Neurology and Neurosurgery. "We commend the investigators for demonstrating ClotChek's ability to better inform clinical decision-making in AIS patients," said Sasha Bakhru, PhD, co-author and CEO of Perosphere. "These findings reinforce the value of our point-of-care ClotChek coagulometer in delivering a rapid assessment of anticoagulant effect, particularly for patients on DOAC therapy with the potential to improve care and outcomes." Oral Poster Presentation Title: Variable Rate of Anticoagulation Response to Direct Oral Anticoagulants (DOACs) in Acute Ischemic Stroke: The Potential of Point-of-Care DOAC Anticoagulation Measurement Presenter: Dr. med. Kamran Hajiyev Date: Wednesday, February 4, 2026 Time/Location: 12:30–2:30 p.m. CST For more information, visit #ISC26: . About Perosphere Perosphere develops point-of-care diagnostics to support informed clinical decision-making for patients receiving anticoagulant therapy or at risk of bleeding. The Perosphere ClotChek™, is a DOAC sensitive coagulometer designed to rapidly measure whole blood clotting time in 3-8 minutes. Perosphere ClotChek is CE marked in the European Union and is not cleared for use by the FDA in the United States. Media Contact: John Friedl j.friedl@perospheretech.com +1 (949) 485-0465 Company Contact: Perosphere info@perospheretech.com +1 (475) 218-4600 View original content to download multimedia: SOURCE Perosphere Technologies Inc.